Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport for the Treatment of Cervical Dystonia

Next Previous
Trial Profile

A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport for the Treatment of Cervical Dystonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Therapeutic Use
  • Sponsors Ipsen

Most Recent Events

  • 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
  • 14 Mar 2017 According to an Ipsen media release, health Canada has approved Dysport (abobotulinumtoxinA) in the treatment of adult patients with Cervical Dystonia; the approval was based on data from this and extension study.
  • 21 Apr 2016 Primary endpoint [Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)] has been met, according to Results presented at the 68th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top